Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement

Frontiers in Pharmacology

DOI: 10.3389/fphar.2026.1891349 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 0 stored of 0

References 6

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent

407

citations
The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics
2023 American Journal of Transplantation article Medicine Renal Transplantation Outcomes and Treatments Open access

293

citations
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
2022 American Journal of Nephrology article Immunology and Microbiology Complement system in diseases Open access

70

citations
The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms
2024 Drug Discovery Today article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent

24

citations
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy
2025 Transplantation and Cellular Therapy article Immunology and Microbiology Complement system in diseases Open access

13

citations
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases

4

citations

6 results